Efficacy of Everolimus and Tolerability with Long-Term Use Abstract #568

Introduction: Predictors of response to Everolimus in neuroendocrine tumors and long-term safety data are lacking.
Aim(s): To assess disease control rate (DCR) and progression-free survival (PFS) with respect to the number of prior treatment lines and evaluation of frequency and timeframe of pneumonitis.
Materials and methods: We analyzed 60 patients (pts) treated with Everolimus +/- Octreotide LAR 30 mg. Median follow-up was 15 months. Location of primary tumor (PT) was in the pancreas or ileum in 24 cases each (41%), respectively, followed by lung (9%, n=5) and others (CUP, rectum, stomach).
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Maximilian Heetfeld

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2829 Everolimus-Induced Pneumonitis in Patients with Neuroendocrine Neoplasms: Multinational Study on Risk Factors and Outcomes
Introduction: The incidence and risk factors for everolimus-induced pneumonitis (EiP) have been poorly studied in patients (pts) with neuroendocrine neoplasms (NEN) outside of clinical trials.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: MD Rodrigo G Taboada
#1417 Everolimus (EVE) Safety Profile in Patients (pts) with Advanced G1-G2 Neuroendocrine Tumours (NETs) from Daily Clinical Practice
Introduction: EVE has shown an overall favourable and well-characterized safety profile in randomized studies including advanced G1-G2 NETs. However, few data outside regulatory trials are available.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: MD PhD Ana Custodio
#2695 Different Treatment Options for Patients with Advanced Gastrointestinal Neuroendocrine Tumors
Introduction: Low sensitivity to chemotherapy leaves open question of optimal approach to drug therapy of neuroendocrine tumors (NETs). Somatostatin analogues (SSA) (octreotide, lanreotide) and mTOR inhibitors are successfully used in treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Alina Isiangulova
Authors: Isiangulova A, Khasanov R, ...
#2884 An Infectious Diseases Specialist NET Patient Looks at Management of NETs
Introduction: Medical specialties may develop practices minimally influenced by other specialties.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Doctor George Schmid
Authors: Schmid G, ...
#483 Efficacy of Everolimus in Patients with Metastatic Insulinomas and Refractory Hypoglycemia: For the French Group of Endocrine Tumors (GTE-Renaten)
Introduction: Refractory hypoglycemia in patients with metastatic insulinomas (RHMI) is an important cause of morbidity and mortality and Everolimus could be a new therapeutic option.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Miss Valérie Bernard